Welcome to CDC stacks | PrEP pill - 44100 | Stephen B. Thacker CDC Library collection
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Filetype[PDF-137.96 KB]


Details:
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like:
  1. Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East Africa
    Personal Author:
    Haberer, Jessica E.; Baeten, Jared M.; Campbell, James; Wangisi, Jonathan; Katabira, Elly; Ronald, Allan; Tumwesigye, Elioda; Psaros, Christina; Safren, Steven A.; Ware, Norma C.; Thomas, Katherine K.; Donnell, Deborah; Krows, Meighan; Kidoguchi, Lara; Celum, Connie; Bangsberg, David R.;
    Published:
    Sep 10 2013
    Source:
    PLoS Med. 2013; 10(9).
    Description:
    Jessica Haberer and colleagues investigate the association between high adherence to antiretroviral pre-exposure prophylaxis and HIV transmission in a substudy of serodiscordant couples participating in a clinical trial. : Background : Randomized cli...
    File Type:
    Filetype[PDF - 270.27 KB]
  2. Factors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitabine as Pre-exposure Prophylaxis (PreP) Clinical Trial, Botswana, 2007-2010
    Personal Author:
    Kebaabetswe, Poloko M.; Stirratt, Michael J.; McLellan-Lemal, Eleanor; Henderson, Faith L.; Gray, Simone C.; Rose, Charles E.; Williams, Tiffany; Paxton, Lynn A.;
    Published:
    May 2015
    Source:
    AIDS Behav. 19(5):758-769.
    Description:
    This study examined study product adherence and its determinants in the Botswana oral pre-exposure prophylaxis efficacy trial. Among the 1,219 participants, the mean adherence by pill count and 3-day self-report was 94 % for each. In multivariable mo...
    File Type:
    Filetype[PDF - 306.01 KB]
  3. Pre-exposure prophylaxis (PrEP) for HIV prevention
    Corporate Author:
    National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of HIV/AIDS Prevention.
    Published:
    5/14/14
    Description:
    Pre-exposure prophylaxis, or PrEP, is a way for people who do not have HIV to help prevent HIV infection by taking a pill every day. The pill contains two medicines that are also used, in combination with other medicines, to treat HIV. When someone i...
    File Type:
    Filetype[PDF - 131.06 KB]
  4. CDC trials : pre-exposure prophylaxis for HIV prevention
    Corporate Author:
    National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Centers for Disease Control and Prevention (U.S.).
    Published:
    February 2011
    Source:
    CDC fact sheet
    Description:
    New tools to prevent HIV are urgently needed to stem the estimated 2.6 million new HIV infections that occur worldwide each year. Recent research has shown that a new approach called pre-exposure prophylaxis, or PrEP, can reduce the risk of contracti...
    File Type:
    Filetype[PDF - 615.54 KB]
  5. PrEP; a new tool for HIV prevention
    Corporate Author:
    National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.)
    Published:
    August 2012
    Series:
    CDC fact sheet
    Description:
    Pre-exposure prophylaxis, or PrEP, is a new HIV prevention method in which people who do not have HIV infection take a pill daily to reduce their risk of becoming infected. The pill contains medicines that prevent HIV from making new virus as it ente...
    File Type:
    Filetype[PDF - 162.24 KB]